The estimated Net Worth of Paul Brons is at least $4.62 Millón dollars as of 9 June 2020. Mr. Brons owns over 2,328 units of Henry Schein stock worth over $1,019,696 and over the last 19 years he sold HSIC stock worth over $3,322,331. In addition, he makes $278,200 as Independent Director at Henry Schein.
Paul has made over 11 trades of the Henry Schein stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 2,328 units of HSIC stock worth $150,505 on 9 June 2020.
The largest trade he's ever made was exercising 15,000 units of Henry Schein stock on 12 February 2014 worth over $561,750. On average, Paul trades about 1,630 units every 59 days since 2006. As of 9 June 2020 he still owns at least 15,208 units of Henry Schein stock.
You can see the complete history of Mr. Brons stock trades at the bottom of the page.
Paul Brons serves as Independent Director of the Company. Between 1994 and 2002, Mr. Brons served as an executive board member of Akzo Nobel, N.V. From 1965 to 1994, Mr. Brons held various positions with Organon International BV, including President from 1983 to 1994 and Deputy President from 1979 to 1983. From 1975 to 1979, Mr. Brons served as the General Manager of the OTC operations of Chefaro, and from 1965 to 1975 in marketing and general management functions for Organon in various Middle East and Latin American countries. Both Organon and Chefaro operated within the Akzo Nobel group. Mr. Brons brings to the Company’s Board of Directors knowledge of the human and animal health pharmaceutical industry (a part of our medical and animal health businesses) and experience with international business operations and relations. The Board of Directors is also aided by Mr. Brons’ knowledge of European business culture and his strategic focus on European health care issues. Mr. Brons was honored in 1996 by Her Majesty the Queen with the decoration of Knight of the Order of Lion of the Kingdom of the Netherlands, the country’s highest civilian order, conferred for his meritorious achievements for Akzo Nobel and other international activities.
As the Independent Director of Henry Schein, the total compensation of Paul Brons at Henry Schein is $278,200. There are 18 executives at Henry Schein getting paid more, with Stanley Bergman having the highest compensation of $14,422,900.
Paul Brons is 78, he's been the Independent Director of Henry Schein since 2005. There are 1 older and 31 younger executives at Henry Schein. The oldest executive at Henry Schein Inc. is Barry Alperin, 79, who is the Independent Director.
Paul's mailing address filed with the SEC is C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE, NY, 11747.
Over the last 22 years, insiders at Henry Schein have traded over $272,732,340 worth of Henry Schein stock and bought 23,637 units worth $1,414,559 . The most active insiders traders include Stanley M Bergman, Norman S Matthews y Deborah Derby. On average, Henry Schein executives and independent directors trade stock every 21 days with the average trade being worth of $1,074,342. The most recent stock trade was executed by Lorelei Mc Glynn on 6 September 2024, trading 21,035 units of HSIC stock currently worth $1,457,726.
henry schein, inc. is the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners. the company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. a fortune 500® company and a member of the s&p 500® and nasdaq 100® indexes, henry schein employs more than 18,000 team schein members and serves more than one million customers. the company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. henry schein operates through a centralized and automated distribution network, with a selection of more than 100,000 branded products and henry schein private-brand products in stock, as well as more than 150,000 additional products available as special-order items. the company also offers its customers exclusive, innovative technology solutions, including practice
Henry Schein executives and other stock owners filed with the SEC include: